{"id":"ranibizumab-prn","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Conjunctival hemorrhage"},{"rate":"5-10","effect":"Eye pain"},{"rate":"5-10","effect":"Floaters"},{"rate":"5-15","effect":"Intraocular pressure elevation"},{"rate":"0.05-0.1","effect":"Endophthalmitis"},{"rate":"0.1-0.5","effect":"Retinal detachment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab blocks VEGF-A, a key driver of pathological neovascularization and increased vascular permeability in retinal diseases. By neutralizing VEGF-A, it reduces fluid leakage, prevents abnormal vessel formation, and slows disease progression. The PRN (pro re nata/as-needed) dosing regimen involves monthly monitoring with injections administered only when retreatment criteria are met.","oneSentence":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:56.964Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion (branch and central)"},{"name":"Myopic choroidal neovascularization"}]},"trialDetails":[{"nctId":"NCT07007065","phase":"PHASE3","title":"Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":561},{"nctId":"NCT06176352","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-03-06","conditions":"Choroidal Neovascularization Secondary to Pathologic Myopia","enrollment":280},{"nctId":"NCT07389577","phase":"PHASE3","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2022-03-01","conditions":"Wet Age-related Macular Degeneration","enrollment":443},{"nctId":"NCT07269769","phase":"PHASE3","title":"A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD","status":"NOT_YET_RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2026-01-01","conditions":"AMD","enrollment":450},{"nctId":"NCT00527475","phase":"PHASE2","title":"Ranibizumab and Reduced Fluence PDT for AMD","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2007-05","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT02243878","phase":"PHASE3","title":"Stereotactic Radiotherapy for Wet AMD (STAR)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-12","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":411},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT04444492","phase":"PHASE3","title":"Combination of Ranibizumab and Targeted Laser Photocoagulation","status":"RECRUITING","sponsor":"University of Giessen","startDate":"2020-08-25","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":110},{"nctId":"NCT03784443","phase":"PHASE2, PHASE3","title":"Combined Ranibizumab and Iluvien for Diabetic Macular Oedema","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2019-09-01","conditions":"Diabetic Macular Edema, Diabetes","enrollment":""},{"nctId":"NCT02511067","phase":"PHASE2","title":"Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-10-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT03963596","phase":"NA","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Pathologic Myopia","enrollment":122},{"nctId":"NCT03690947","phase":"PHASE4","title":"Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2018-10-01","conditions":"Diabetic Macular Edema","enrollment":72},{"nctId":"NCT03054766","phase":"NA","title":"Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2017-02-14","conditions":"Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation","enrollment":80},{"nctId":"NCT01469156","phase":"PHASE1, PHASE2","title":"Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Southeast Retina Center, Georgia","startDate":"2011-09","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":20},{"nctId":"NCT01610557","phase":"PHASE2","title":"Ranibizumab and Bevacizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2012-05","conditions":"Diabetic Macular Edema","enrollment":56},{"nctId":"NCT03725501","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD","status":"COMPLETED","sponsor":"AngioLab, Inc.","startDate":"2018-12-07","conditions":"Age-Related Macular Degeneration","enrollment":126},{"nctId":"NCT05271539","phase":"PHASE3","title":"Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-07-01","conditions":"Diabetic Macular Edema","enrollment":42},{"nctId":"NCT02348359","phase":"PHASE2","title":"X-82 to Treat Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Tyrogenex","startDate":"2015-03-16","conditions":"Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration","enrollment":157},{"nctId":"NCT04857177","phase":"PHASE3","title":"A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-10-19","conditions":"Neovascular(Wet) Age Related Macular Degeneration","enrollment":312},{"nctId":"NCT02222610","phase":"PHASE2","title":"Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2014-09-23","conditions":"Radiation Retinopathy","enrollment":40},{"nctId":"NCT04245072","phase":"NA","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis","status":"UNKNOWN","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Chorioretinitis","enrollment":100},{"nctId":"NCT04119219","phase":"NA","title":"Antiangiogenic Therapy of CNV Associated With Angioid Streaks","status":"UNKNOWN","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Angioid Streaks of Macula","enrollment":100},{"nctId":"NCT01006538","phase":"PHASE4","title":"Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2009-11","conditions":"Macular Degeneration","enrollment":363},{"nctId":"NCT04601675","phase":"NA","title":"Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2020-10-31","conditions":"Macular Edema","enrollment":100},{"nctId":"NCT02032173","phase":"PHASE3","title":"Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-19","conditions":"Macular Edema, Macular Degeneration, Diabetes","enrollment":31},{"nctId":"NCT02358889","phase":"PHASE2","title":"Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Iconic Therapeutics, Inc.","startDate":"2015-02","conditions":"Choroidal Neovascularization, Age-related Macular Degeneration","enrollment":88},{"nctId":"NCT00764738","phase":"PHASE2, PHASE3","title":"Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Retina Macula Institute","startDate":"2008-10","conditions":"Neovascular Age Related Macular Degeneration","enrollment":91},{"nctId":"NCT01223612","phase":"PHASE4","title":"Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2010-10","conditions":"Diabetic Retinopathy","enrollment":37},{"nctId":"NCT04387604","phase":"","title":"Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Centro Hospitalar do Porto","startDate":"2017-08-01","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT02953938","phase":"PHASE4","title":"Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-15","conditions":"Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)","enrollment":59},{"nctId":"NCT00656903","phase":"","title":"High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2008-04-07","conditions":"Macular Degeneration","enrollment":75},{"nctId":"NCT02665689","phase":"PHASE4","title":"Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab","status":"TERMINATED","sponsor":"Prof. Dr. Antonia M. Joussen","startDate":"2016-01-18","conditions":"Visual Acuity Reduced Transiently, Macular Edema, Cystoid","enrollment":4},{"nctId":"NCT02976194","phase":"PHASE4","title":"Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2016-11-22","conditions":"Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy","enrollment":28},{"nctId":"NCT01795209","phase":"PHASE4","title":"Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision","status":"TERMINATED","sponsor":"Seoul National University Bundang Hospital","startDate":"2013-01","conditions":"Branch Retinal Vein Occlusion, Macular Edema","enrollment":19},{"nctId":"NCT02769169","phase":"PHASE2, PHASE3","title":"Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2018-08-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":5},{"nctId":"NCT01775124","phase":"PHASE4","title":"Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-22","conditions":"Neovascular Age-related Macular Degeneration","enrollment":332},{"nctId":"NCT04062370","phase":"PHASE4","title":"Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-01","conditions":"Retinal Vein Occlusion, Treatment, Photocoagulation Burn to Retina","enrollment":100},{"nctId":"NCT02478515","phase":"PHASE4","title":"Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Nagoya City University","startDate":"2014-01","conditions":"Branch Retinal Vein Occlusion","enrollment":27},{"nctId":"NCT01464723","phase":"PHASE4","title":"Study EvAluating Genotypes While Using Lucentis 2","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-05","conditions":"Age-Related Macular Degeneration","enrollment":66},{"nctId":"NCT01908816","phase":"PHASE3","title":"An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-26","conditions":"Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascular","enrollment":270},{"nctId":"NCT03973138","phase":"PHASE1, PHASE2","title":"Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-01-01","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT01492400","phase":"PHASE2","title":"Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-03-09","conditions":"Macular Edema","enrollment":363},{"nctId":"NCT01958918","phase":"PHASE4","title":"Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":712},{"nctId":"NCT03042871","phase":"PHASE4","title":"Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2015-04","conditions":"Choroidal Neovascularization","enrollment":54},{"nctId":"NCT02140411","phase":"PHASE4","title":"Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04-25","conditions":"Retinal Vein Occlusion, Age Related Macular Degeneration","enrollment":21},{"nctId":"NCT02161575","phase":"PHASE4","title":"Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":103},{"nctId":"NCT02259088","phase":"PHASE3","title":"A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-05","conditions":"Diabetic Macular Edema, Visual Impairment","enrollment":384},{"nctId":"NCT02366468","phase":"PHASE4","title":"Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-02-23","conditions":"Diabetic Retinopathy","enrollment":135},{"nctId":"NCT02107131","phase":"PHASE4","title":"Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab","status":"COMPLETED","sponsor":"California Retina Consultants","startDate":"2015-03-13","conditions":"Diabetic Macular Edema","enrollment":40},{"nctId":"NCT01552408","phase":"PHASE1, PHASE2","title":"Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)","status":"COMPLETED","sponsor":"David M. Brown, M.D.","startDate":"2012-03","conditions":"Diabetic Macular Edema","enrollment":29},{"nctId":"NCT02591914","phase":"PHASE1","title":"An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2014-02","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":30},{"nctId":"NCT02294656","phase":"PHASE1","title":"Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide","status":"COMPLETED","sponsor":"Soll Eye","startDate":"2014-11","conditions":"CYSTOID MACULAR EDEMA","enrollment":4},{"nctId":"NCT01674569","phase":"PHASE1, PHASE2","title":"Pilot Study of X-82 in Patients With Wet AMD","status":"COMPLETED","sponsor":"Tyrogenex","startDate":"2012-10","conditions":"Exudative Macular Degeneration","enrollment":35},{"nctId":"NCT01941329","phase":"PHASE2, PHASE3","title":"Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2014-04","conditions":"High Risk Proliferative Diabetic Retinopathy","enrollment":94},{"nctId":"NCT02329132","phase":"","title":"Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Kagawa University","startDate":"2015-11","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT03459144","phase":"NA","title":"Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2012-12-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT01134055","phase":"PHASE2","title":"Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-01","conditions":"Macular Degeneration","enrollment":510},{"nctId":"NCT02843490","phase":"PHASE4","title":"Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2016-08-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":71},{"nctId":"NCT00498355","phase":"PHASE1, PHASE2","title":"Lucentis for Inflammatory Macular Edema Trial","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-07","conditions":"Uveitis, Cytoid Macular Edema","enrollment":7},{"nctId":"NCT01025063","phase":"","title":"Use of Spectral OCT in Combination Therapy","status":"COMPLETED","sponsor":"Barnes Retina Institute","startDate":"2008-01","conditions":"Choroidal Neovascularization","enrollment":15},{"nctId":"NCT01863199","phase":"PHASE4","title":"Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2013-05","conditions":"Neovascular Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT01710839","phase":"PHASE4","title":"Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Charles C Wykoff, PhD, MD","startDate":"2012-10","conditions":"Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions","enrollment":30},{"nctId":"NCT03261635","phase":"PHASE4","title":"Ranibizumab Plus Indomethacin","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2016-01-07","conditions":"Macular Edema","enrollment":58},{"nctId":"NCT01225146","phase":"PHASE1","title":"Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)","status":"TERMINATED","sponsor":"David M. Brown, M.D.","startDate":"2010-10","conditions":"Ischemia, Retinal Vein Occlusion, Pathologic Processes","enrollment":8},{"nctId":"NCT00931489","phase":"PHASE2","title":"Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Lawrence S. Morse, MD","startDate":"2009-08","conditions":"Age Related Macular Degeneration","enrollment":131},{"nctId":"NCT01976312","phase":"PHASE3","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-12","conditions":"Central Retinal Vein Occlusion","enrollment":252},{"nctId":"NCT00379795","phase":"NA","title":"An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-04","conditions":"Choroidal Neovascularization, Age-related Macular Degeneration","enrollment":853},{"nctId":"NCT01976338","phase":"PHASE3","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-12","conditions":"Macular Edema Secondary to Branch Retinal Vein Occlusion","enrollment":283},{"nctId":"NCT00473330","phase":"PHASE3","title":"A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Diabetes Mellitus, Macular Edema","enrollment":377},{"nctId":"NCT00473382","phase":"PHASE3","title":"A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Diabetes Mellitus, Macular Edema","enrollment":382},{"nctId":"NCT00407381","phase":"PHASE2","title":"The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2006-12","conditions":"Diabetic Macular Edema","enrollment":126},{"nctId":"NCT01543568","phase":"PHASE4","title":"Study for Recalcitrant Age Related Macular Degeneration","status":"COMPLETED","sponsor":"David M. Brown, M.D.","startDate":"2012-02","conditions":"Age Related Macular Degeneration","enrollment":46},{"nctId":"NCT01599650","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Branch Retinal Vein Occlusion","enrollment":455},{"nctId":"NCT02810808","phase":"PHASE4","title":"Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2013-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":115},{"nctId":"NCT01535261","phase":"PHASE3","title":"Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02","conditions":"Macular Edema, Central Retinal Vein Occlusion","enrollment":357},{"nctId":"NCT01213667","phase":"PHASE4","title":"Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD","status":"UNKNOWN","sponsor":"University of Cologne","startDate":"2010-01","conditions":"Macular Degeneration","enrollment":110},{"nctId":"NCT00561834","phase":"PHASE1","title":"Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-11","conditions":"Nonarteritic Anterior Ischemic Optic Neuropathy","enrollment":2},{"nctId":"NCT01840410","phase":"PHASE3","title":"Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09","conditions":"Choroidal Neovascularization (CNV)","enrollment":183},{"nctId":"NCT02864472","phase":"PHASE4","title":"Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-09","conditions":"Age-related Macular Degeneration","enrollment":40},{"nctId":"NCT00517010","phase":"EARLY_PHASE1","title":"Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2007-05","conditions":"Age-related Macular Degeneration","enrollment":6},{"nctId":"NCT02349516","phase":"PHASE2","title":"Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)","status":"WITHDRAWN","sponsor":"Starr Muscle","startDate":"2015-02","conditions":"Diabetic Retinopathy","enrollment":""},{"nctId":"NCT01846299","phase":"PHASE3","title":"To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Macular Edema (ME)","enrollment":181},{"nctId":"NCT01580020","phase":"PHASE4","title":"Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Retinal Vein Occlusion","enrollment":175},{"nctId":"NCT01810042","phase":"PHASE4","title":"Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2010-10","conditions":"Exudative Age-related Macular Degeneration","enrollment":49},{"nctId":"NCT01189019","phase":"PHASE2","title":"HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Anne Fung MD","startDate":"2010-08","conditions":"Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment","enrollment":40},{"nctId":"NCT01003106","phase":"PHASE1, PHASE2","title":"Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions","status":"COMPLETED","sponsor":"Peter A Campochiaro, MD","startDate":"2009-11","conditions":"Retinal Vein Occlusion","enrollment":81},{"nctId":"NCT00423189","phase":"PHASE4","title":"Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration","status":"TERMINATED","sponsor":"David M. Brown, M.D.","startDate":"2007-01","conditions":"Age-Related Macular Degeneration","enrollment":7},{"nctId":"NCT01827722","phase":"PHASE4","title":"Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Valley Retina Institute","startDate":"2013-05","conditions":"Macular Edema, Central Retinal Vein Occlusion","enrollment":45},{"nctId":"NCT02614937","phase":"PHASE1, PHASE2","title":"Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Ohr Pharmaceutical Inc.","startDate":"2013-04","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":20},{"nctId":"NCT02527733","phase":"PHASE4","title":"Retinal Sensitivity in BRVO After Anti-VEGF Therapy","status":"UNKNOWN","sponsor":"Fukushima Medical University","startDate":"2015-06","conditions":"Branch Retinal Vein Occlusion","enrollment":50},{"nctId":"NCT00896779","phase":"PHASE2","title":"Lucentis in Advanced Macular Degeneration","status":"COMPLETED","sponsor":"Steven R. Sanislo","startDate":"2009-10","conditions":"Macular Degeneration","enrollment":20},{"nctId":"NCT01500915","phase":"PHASE4","title":"FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Institut de la Macula y la Retina","startDate":"2010-11","conditions":"Exudative Age-related Macular Degeneration","enrollment":17},{"nctId":"NCT01581151","phase":"NA","title":"Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Brian Burke, MPH","startDate":"2011-09","conditions":"Retinal Vein Occlusion","enrollment":30},{"nctId":"NCT01291121","phase":"NA","title":"Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-02","conditions":"Neovascular Age-related Macular Degeneration","enrollment":30},{"nctId":"NCT01016873","phase":"PHASE2","title":"INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD","status":"COMPLETED","sponsor":"Oraya Therapeutics, Inc.","startDate":"2009-11","conditions":"AMD, Wet AMD, Age-Related Macular Degeneration","enrollment":230},{"nctId":"NCT01175395","phase":"PHASE1, PHASE2","title":"20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2010-09","conditions":"Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":10},{"nctId":"NCT01334879","phase":"PHASE1","title":"High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy","status":"COMPLETED","sponsor":"The New York Eye Cancer Center","startDate":"2011-05","conditions":"Radiation Retinopathy","enrollment":10},{"nctId":"NCT01845844","phase":"PHASE1, PHASE2","title":"Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab","status":"UNKNOWN","sponsor":"Southeast Retina Center, Georgia","startDate":"2013-04","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT01171976","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab in Two \"Treat and Extend\" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Diabetic Macular Edema","enrollment":373}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lucentis"],"phase":"marketed","status":"active","brandName":"ranibizumab PRN","genericName":"ranibizumab PRN","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}